CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'
Robert Greifeld, Nasdaq CEO, discusses bank earnings, the IPO market, and more at the eMerge Americas conference.
Federal regulators are investigating blood-testing start-up Theranos over whether it misled investors.
Adam Parker, Morgan Stanley chief U.S. equity strategist, thinks biotech and pharma look attractive, in discussing his market forecast.
Following his announcement to donate $250 million for cancer research, Sean Parker joined CNBC to discuss his initiative.
David Seaburg, Cowen & Company Head of Sales & Trading, and Tobias Levkovich, Citi Chief U.S. Equity Strategist, discuss the current state of the markets going into earnings season.
Discussing drug pricing, product approvals in the health care industry, and what's to come from the sector, with Matt Maley, Miller Tabak managing director & equity strategist, and Ian Somaiya, BMO Capital biotech analyst.
Is it time to buy biotech as the sector is breaking out?
The FMHR traders look at retail earnings, and the health of biotech stocks right now.
BehavioSec provides biometric security to customers. Its founder, Olov Renberg discusses fundraising and why banks are intrigued by BehavioSec’s product.
Les Funtleyder, E Squared Asset Management Portfolio Manager, and David Seaburg, Cowen & Company Managing Director and Head of Sales & Trading, discuss the biotech sector and how investors should approach it.
FMHR trader Jim Lebenthal says biotech goes higher from here as the sector continues to fade. The FMHR traders discuss pressure from the presidential campaign on the biotech space.
Biotechs are still sinking, so when should you buy these stocks? The FMHR traders and Stephanie Link, TIAA Equities portfolio manager, share their strategy.
Les Funtleyder, E Squared Asset Management, and CNBC's Meg Tirrell, discuss whether there is more pain to come in biotech and if the pullback presents a buying opportunity.
The number one biotech analyst Mark Schoenebaum, Evercore ISI pharma analyst, weighs in on the selloff in the space, and which stocks have the potential to go higher this year.
RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.
Bill Miller, LMM chairman & CIO, weighs in on why he likes auto stocks and biotech company Intrexon.
Michel Demaré, chairman of Syngenta, says the takeover deal with state-owned ChemChina is good value for shareholders.
Regulators warn that new Theranos lab in California is unsafe for patients, company says it's taking corrective action. CNBC's Meg Tirrell explains.
After rash of earnings reports, Abbott Labs, Bristol-Myers Squibb, Celgene and Eli Lilly shares suffer. CNBC's Meg Tirrell reports.